Methods: 100 patients with acute exacerbation of schizophrenia were randomly put on flexible dose of amisulpride (200-1000mg/day) or risperidone (2-10mg/day) for six weeks after three to six day placebo wash-out period. Efficacy was assessed by changes in score of Brief Psychiatry Rating Scale (BPRS). Safety assessment was done by adverse event reporting, physical examination, blood pressure, heart rate monitoring and applying modified Simpson-Angus Scale for extra pyramidal symptoms.
Results:
Most of the patients in both group responded equally to medication. 84% of amisulpride receiving patients versus 86% in risperidone group responded to treatment. Both drugs were safe and caused comparable extra pyramidal symptoms (amisulpride/risperidone: 14/16). However, risperidone caused more weight gain than amisulpride (64% vs. 12%).
Conclusion:
Amisulpride and risperidone are equally effective in the treatment of acute exacerbation of schizophrenia. Both drugs were well tolerated. Amisulpride was associated with less weight gain. Patients aged between 15 to 60 years who fulfilled the diagnostic criteria of Schizophrenia according to ICD-10, with acute exacerbation of symptoms were included in this study. Only the patients whose relatives or caretaker had given written consent to participate in this study were included.
INTRODUCTION
Exclusion Criteria:
Patients having gross organic brain disorders, symptoms of substance related withdrawal, severe medical illness, mental retardation, past history of non-response to at least two wellvalidated antipsychotics, and the patients who have been on continuous antipsychotic treatment for more than one week immediately prior to our contact were excluded from the study. Uncooperative patients, pregnant or breast feeding women were also excluded from the study.
Half of the patients were randomly started on flexible dose of amisulpride (200-1000mg/day) and the remaining half on risperidone (2-10mg/day) following a three-to six-day placebo wash-out period. Patients were followed up for six weeks. Patients who showed more than 20% improvement on the BPRS total score during the placebo washout period were excluded from the study. The doses were set at a ratio of 1mg risperidone to 100 mg amisulpride. 
RESULTS
Out of the fifty patients receiving risperidone, forty three (86%) of them showed good response in their symptoms, whereas 7 patients (14%) showed poor response (less than fifty percent improvement) to treatment. Among amisulpride receiving patients, forty two patients (84%) showed good response to treatment. Eight patients (16%) had poor response to treatment. At df=1, and p=0.05 chisquare tabulated value was 3.841, whereas our calculated chisquare value was 0.0777. So this difference in efficacy was not statistically significant.
Sixteen patients (32%) receiving risperidone had clinically significant degree of movement disorders, with Modified Simpson-Angus Scale (MSAS) score more than five. Two patients (4%) had minimal degree of movement disorder, with MSAS score ranging from three to five. In the amisulpride group, fourteen patients (28%) had clinically significant movement disorder. Five patients (10%) had minimal degree of movement disorder. Weight gain was considered to be significant if there was more than five percent increase in body weight after one month of start of medicine. Thirty two patients (64%) in risperidone group had more than five percent body weight gain from the baseline. On the other hand, in amisulpride group, only six patients (12%) had significant weight gain. (Table 2) The tabulated chiquare value for df=1 at p= 0.05, is x 2 = 3.841 which is greater than calcutaed x 2 = 28.69, so this difference in increase in body weight among amisulpride and risperidone was statistically significant.
There were no clinically relevant changes in vital signs in either group.
DISCUSSION
The above result shows that amisulpride is as effective as risperidone in the treatment of acute exacerbation of schizophrenia. Many studies comparing amisulpride with risperidone in schizophrenia have also shown similar result. 2, 4, 5, 6 However, study done by Peuskens J et al.
showed that though both treatments produced a marked improvement in schizophrenic symptomatology. All the individual factors on BPRS showed a numerically greater improvement in the amisulpride than in the risperidone patients.
7
In our study, both drugs were well tolerated and there was not much difference in the incidence of developing EPS in both groups (amisulpride/risperidone: 28%/32%). This finding was in accordance with findings from other studies. 2, 4, 6, 7 Regarding weight gain, in our study significant number of patients receiving risperidone had weight gain compared to amisulpride (64% vs 12%). Our study supports similar findings got from other studies. 2, 6, 7 There was no clinically relevant change in blood pressure, heart rate in both amisulpride and risperidone group, as shown in other studies.
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Study done by Hwang TJ et al. showed that patients receiving amisulpride had reduction of blood pressure and heart rate. Although statistically significant, this finding was not found to be clinically significant.
